Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 6/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.39 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30775064 | 1.00 | PSMB8 (0.48) | PSMB8KDM4EALDH1A1HPGDCYP3A4 | |
| SCHEMBL338855 | 0.76 | KDM4E (0.42) | KDM4EALDH1A1METAP1NUDT1PARP1 | |
| SCHEMBL1761836 | 0.69 | PSMB8 (0.50) | PSMB8KDM4EALDH1A1HPGDCYP3A4 | |
| SCHEMBL29967361 | 0.69 | PSMB8 (0.50) | PSMB8KDM4EALDH1A1HPGDCYP3A4 | |
| SCHEMBL742960 | 0.68 | HTT (0.31) | PSMB8KDM4EALDH1A1HPGDCYP3A4 | |
| 2-Mercaptobenzothiazole SCHEMBL29433968 | 0.66 | PSMB8 (1.00) | PSMB8KDM4EALDH1A1HPGDCYP3A4 | |
| SCHEMBL12642502 | 0.66 | — | — | |
| 2-Mercaptobenzothiazole SCHEMBL408087 | 0.66 | PSMB8 (1.00) | PSMB8KDM4EALDH1A1HPGDCYP3A4 | |
| 2-Mercaptobenzothiazole SCHEMBL8749352 | 0.64 | PSMB8 (0.95) | PSMB8KDM4EALDH1A1HPGDCYP3A4 | |
| 2-Mercaptobenzothiazole SCHEMBL4268289 | 0.64 | PSMB8 (0.95) | PSMB8KDM4EALDH1A1HPGDCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3676261-B1 | SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | CHRONOS THERAPEUTICS LTD (GB) | 2024-12-18 | — | — | EP | disclosed |
| US-11660293-B2 | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists | CHRONOS THERAPEUTICS LIMITED (GB) | 2023-05-30 | — | — | US | disclosed |
| US-11660293-B2 | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists | CHRONOS THERAPEUTICS LIMITED (GB) | 2023-05-30 | — | — | US | disclosed |
| US-11660293-B2 | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists | CHRONOS THERAPEUTICS LIMITED (GB) | 2023-05-30 | — | — | US | disclosed |
| US-20220331299-A1 | SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | CHRONOS THERAPEUTICS LIMITED (GB) | 2022-10-20 | — | — | US | disclosed |
| WO-2019043407-A1 | SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | CHRONOS THERAPEUTICS LIMITED (GB) | 2019-03-07 | — | — | WO | disclosed |
| US-9382425-B2 | Aza-benzazolium containing cyanine dyes | Life Technologies Corporation (US) | 2016-07-05 | — | — | US | disclosed |
| US-20150031579-A1 | Aza-Benzazolium Containing Cyanine Dyes | MOLECULAR PROBES, INC. | 2015-01-29 | — | — | US | disclosed |
| US-8883415-B2 | Aza-benzazolium containing cyanine dyes | Life Technologies Corporation (US) | 2014-11-11 | — | — | US | disclosed |
| US-20130178395-A1 | Aza-Benzazolium Containing Cyanine Dyes | Life Technologies Corporation (US) | 2013-07-11 | — | — | US | disclosed |
| US-20080124732-A1 | METHOD FOR OPTICAL MEASUREMENT OF MULTI-STRANDED NUCLEIC ACID | FUJIFILM CORPORATION | 2008-05-29 | — | — | US | disclosed |
| US-20080044811-A1 | nucleic acid or a poly(amino acid) samples and dyes in form of staining solution are combined for sufficient time to form dye-analyte complex and are illuminated with an appropriate wavelength whereby nucleic acid or a poly(amino acid) is detected | INVITROGEN CORPORATION (US) | 2008-02-21 | — | — | US | disclosed |
| EP-1889880-A2 | Method for optical measurement of multi-stranded nucleic acid | FUJIFILM Corporation (JP) | 2008-02-20 | — | — | EP | disclosed |
| EP-1362894-B1 | Method for optical measurement of multi-stranded nucleic acid using cyanine dyes | FUJIFILM CORP (JP) | 2007-12-19 | — | — | EP | disclosed |
| US-20050112770-A1 | Method for optical measurement of multi-stranded nucleic acid | FUJI PHOTO FILM CO., LTD. | 2005-05-26 | — | — | US | disclosed |
| US-6664047-B1 | Assymetrical; substituted by a cationic side chain; exhibit bright fluorescence when associated with nucleic acid polymers such as DNA or RNA, or with polypeptides | MOLECULAR PROBES, INC. | 2003-12-16 | — | — | US | disclosed |
| EP-1362894-A2 | Method for optical measurement of multi-stranded nucleic acid using cyanine dyes | FUJI PHOTO FILM CO., LTD. (JP) | 2003-11-19 | — | — | EP | disclosed |
| WO-2000066664-A1 | AZA-BENZAZOLIUM CONTAINING CYANINE DYES | MOLECULAR PROBES, INC. (US) | 2000-11-09 | — | — | WO | disclosed |
| EP-0393574-B1 | Hexitol derivatives | KYOWA HAKKO KOGYO KK (JP) | 1996-01-31 | — | — | EP | disclosed |
| EP-0393574-A2 | Hexitol derivatives | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1990-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220331299-A1 | SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY1R | PSMB8 1557/4885KDM4E 2153/4885ALDH1A1 589/4885 |
| US-11660293-B2 | Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists | HCRTR2, HCRTR1, NPY1R | PSMB8 1557/4885KDM4E 2153/4885ALDH1A1 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.